亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Cyclic Amp-Elevating Drugs As Adjuvants - 2014-084

技術優勢: Where current adjuvants act by one or several of the following mechanisms, the Th17-class of adjuvants mediate all of the following: Increase antigen transport and uptake (phagocytosis) by antigen-presenting cells Provide a long-lasting depot effect, i.e., antigenic reservoir for slow release Trigger efficient antigen processing and presentation Induce co-stimulatory molecules and cytokine release by dendritic cells (necessary for the activation of naïve T cells) Provoke additional activation pathways (e.g., pattern-recognition receptors such as Toll-like receptors and the unfolded protein response pathway) These features combine with the simplicity of small molecules and the design of here-to-fore dissimilar vaccines for diverse applications.

技術應用: This formulation of antigen-adjuvant-carrier is envisioned for use in vaccines that are:Delivered systemically or mucosally Therapeutic or prophylactic.

詳細技術說明: In foundational studies, UC researchers observed that cAMP production in a critical subpopulation of cells (i.e., dendritic cells) selectively activated cAMP/PKA pathway. This work has now been applied to the design and testing of a “universal vaccine” formulation, comprising an antigen of interest with a class of Th17 adjuvants and a carrier or additional adjuvant such as alum. The ability to target to the critical cell type enables a powerful adjuvant with improved toxicity profiles, Additionally, the focus on small (<1,000 Da MW), drug-like and non-immunogenic molecules should eliminate immunogenicity problems associated with bacterial polypeptides and biologic agents that raise cAMP levels via an irreversible mechanism.

*Abstract: Effective adjuvants enhance antigen immunogenicity and/or modulate the type of immunity (e.g., humoral vs. cellular immune response), and, in theory, an optimal antigen-adjuvant combination should activate the both arms of the immune system (innate and adaptive immunity). Different adjuvants work via different mechanisms and, ultimately, the best adjuvant for any specific vaccine will be chosen on the basis of compatibility with the delivery route (e.g., systemic vs. mucosal), ability to provoke the desired immune response (e.g., humoral vs. cellular immunity), and relevance to a particular stage of the required anti-microbial protection (e.g., preventive vs. therapeutic immunity). One way to achieve these diverse goals is to use a combination of complementary, synergistic adjuvants and this is one current practice. However, an adjuvant that could trigger the immunomodulatory cascade upstream of current options could simplify the design of safe and effective vaccines and revolutionize modern day vaccinations.

*Principal Investigation: Name: Paul Insel
Department:

Name: Taehun Kim
Department:

Name: Jihyung Lee
Department:

Name: Xiangli Li
Department:

Name: Fiona Murray
Department:

Name: Eyal Raz
Department:

其他

State Of Development

Mice have been immunized and then early indicators of immune response assessed (IL-17 response and titer of Ab vs. immunogen (Anti-OVA IgG)).

Intellectual Property Info

US rights available for licensure. See “Patent Status”, below.

Related Materials

Related Technologies

Tech ID/UC Case

25178/2011-208-0

Related Cases

2011-208-0, 2013-334-0, 2013-282-0

欲了解更多信息，請點擊這裡